BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29967557)

  • 1. Long-term outcomes of alternating chemoradiotherapy in patients with advanced nasopharyngeal cancer: a single-centre experience over the last decade.
    Saijoh S; Matsuzuka T; Sato H; Suzuki M; Ikeda M; Suzuki R; Nakaegawa Y; Omori K
    Acta Otorhinolaryngol Ital; 2018 Apr; 38(2):103-108. PubMed ID: 29967557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting outcomes of alternating chemoradiotherapy for nasopharyngeal cancer.
    Ueno T; Endo K; Kondo S; Wakisaka N; Murono S; Ito M; Yoshizaki T
    Ann Otol Rhinol Laryngol; 2014 Jul; 123(7):509-16. PubMed ID: 24634152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcomes of alternating chemoradiotherapy for nasopharyngeal carcinoma: a single-center safety and efficacy study.
    Ohara K; Takahara M; Kumai T; Yamashina M; Kishibe K; Katada A; Hayashi T
    Braz J Otorhinolaryngol; 2023; 89(3):440-446. PubMed ID: 36682990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
    Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
    Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term outcomes of alternating chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multiinstitutional phase II study.
    Fuwa N; Kodaira T; Daimon T; Yoshizaki T
    Cancer Med; 2015 Aug; 4(8):1186-95. PubMed ID: 25991077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: its usefulness and controversial points.
    Fuwa N; Ito Y; Kodaira T; Matsumoto A; Kamata M; Furutani K; Tatibana H; Sasaoka M; Morita K
    Jpn J Clin Oncol; 2001 Dec; 31(12):589-95. PubMed ID: 11902489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma.
    Takamizawa S; Honma Y; Murakami N; Mori T; Oka H; Yamamoto S; Kashihara T; Ito K; Kubo Y; Ikeda A; Matsumoto F; Omura G; Kobayashi K; Itami J; Kato K; Yoshimoto S
    Invest New Drugs; 2021 Apr; 39(2):564-570. PubMed ID: 32940872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil--a phase II study.
    Fuwa N; Shikama N; Hayashi N; Matsuzuka T; Toita T; Yuta A; Oonishi H; Kodaira T; Tachibana H; Nakamura T; Daimon T
    Oral Oncol; 2007 Oct; 43(9):948-55. PubMed ID: 17257880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
    Jamshed A; Hussain R; Iqbal H
    Asian Pac J Cancer Prev; 2014; 15(2):899-904. PubMed ID: 24568516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
    Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
    Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
    Nakata Y; Ijichi K; Hanai N; Nishikawa D; Suzuki H; Hirakawa H; Kodaira T; Fujimoto Y; Fujii T; Miyazaki T; Shimizu T; Hasegawa Y
    Auris Nasus Larynx; 2017 Feb; 44(1):104-110. PubMed ID: 27435048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis.
    Saleh-Ebrahimi L; Zwicker F; Muenter MW; Bischof M; Lindel K; Debus J; Huber PE; Roeder F
    Radiat Oncol; 2013 Jan; 8():20. PubMed ID: 23347410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
    Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study.
    Shim HJ; Kim HJ; Hwang JE; Bae WK; Chung IJ; Lee DH; Mi YT; Lee JK; Lim SC; Chung JW; Cho SH
    Medicine (Baltimore); 2020 Dec; 99(49):e23173. PubMed ID: 33285692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma.
    Komatsu M; Arai Y; Yabuki K; Sano D; Shiono O; Sakuma Y; Nishimura G; Takahashi M; Taguchi T; Oridate N
    Anticancer Res; 2015 Dec; 35(12):6861-7. PubMed ID: 26637908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
    Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J
    Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Liu LT; Liu H; Huang Y; Yang JH; Xie SY; Li YY; Guo SS; Qi B; Li XY; Chen DP; Jin F; Sun XS; Yang ZC; Liu SL; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Qiu F; Yang Q; Liang YJ; Jia GD; Wen DX; Yan JJ; Zhao C; Chen QY; Sun R; Tang LQ; Mai HQ
    Lancet Oncol; 2023 Jul; 24(7):798-810. PubMed ID: 37290468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.